NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial - NovoCure (NASDAQ:NVCR), Zai Lab (NASDAQ:ZLAB)

Disrupting cancer cell division: How tumour treating fields are changing oncology

Tumour Treating Fields disrupt cancer cell division—discover how this innovative therapy is transforming pancreatic cancer treatment with insights from Dr. Vincent Picozzi at ASCO 2025.

Survival in Unresectable Pancreatic Cancer Improved With Tumor Treating Fields

(MedPage Today) -- CHICAGO -- For the first time in a phase III trial, overall survival (OS) in unresectable pancreatic cancer improved significantly versus chemotherapy with the addition of tumor treating fields (TTFields). Median OS increased...

NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial - NovoCure (NASDAQ:NVCR), Zai Lab (NASDAQ:ZLAB)

Zai Lab Limited (NASDAQ:ZLAB) and NovoCure Limited (NASDAQ:NVCR) revealed additional data on Saturday from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy for pancreatic cancer. The data were presented at the 2025 American Society of Clinical Oncology Annual Meeting. The Phase 3 PANOVA-3 trial evaluated the use of TTFields therapy concomitantly with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable,…

Research Spotlight by Dr. Anna Berkenblit: June 2025

Jun 23, 2025 - By Anna Berkenblit, MD, MMScEditor’s note: The “Research Spotlight” series is written by Dr. Anna Berkenblit, PanCAN’s Chief Scientific and Medical Officer. Each month, Dr. Berkenblit shares her insights into the latest news and research in pancreatic cancer. Follow Dr. Berkenblit on X and LinkedIn. Key Takeaways on Pancreatic Cancer from the 2025 ASCO Annual Meeting Every year, the American Society of Clinical Oncology (ASCO) Ann…

TTFields Show Significant Survival Benefit in Pancreatic Cancer

Vincent Picozzi, MD, discusses findings from the phase 3 trial PANOVA-3 of TTFields with gemcitabine and nab-paclitaxel in locally advanced pancreatic cancer.

#Promising Advances in Pancreatic Cancer Treatment Zai Lab and Novocures PANOVA-3 Trial Results

In recent developments within the healthcare sphere, Zai Lab Limited (NASDAQ: ZLAB) and Novocure Limited (NASDAQ: NVCR) have announced significant results from their Phase 3 PANOVA-3 trial, which investigated the efficacy of Tumor Treating Fields (TTFields) therapy for treating pancreatic cancer. The promising findings from this trial are set to be presented at the upcoming 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO),…